Bayesian dose finding for combined drugs with discrete and continuous doses

Bayesian Analysis

Volumn 7, Issue 4, 2012, Pages 1035-1052

  Huo, Lin ^a   Yuan, Ying ^b   Yin, Guosheng ^c  

^a NOVARTIS PHARMA AG   (Switzerland)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Bayesian adaptive design; Combined drugs; Continual reassessment method; Maximum tolerated dose; Phase I trial; Toxicity probability; Two stage design

Indexed keywords

EID: 84872576106     PISSN: 19360975     EISSN: 19316690     Source Type: Journal    
DOI: 10.1214/12-BA735     Document Type: Article

References (21)

1. Braun, T. M. and Wang, S. (2010). "A hierarchical Bayesian design for phase I trials of novel combinations of cancer therapeutic agents." Biometrics, 66: 805-812.
2. Chevret, S. (2006). Statistical Methods for Dose-Finding Experiments. London: John Wiley&Sons Ltd.
3. Goodman, S. N., Zahurak, M. L., and Piantadosi, S. (1995). "Some practical im- provements in the continual reassessment method for phase I studies." Statistics in Medicine, 14: 1149-1161.
4. Heyd, J. M., and Carlin, B. P. (1999). "Adaptive design improvements in the continual reassessment method for phase I studies." Statistics in Medicine, 18: 1307-1321.
5. Ishizuka, N., and Ohashi, Y. (2001). "The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials." Statistics in Medicine, 20: 2661-2681.
6. Korn, E. L. and Simon, R. (1993). "Using the tolerable-dose diagram in the design of phase I combination chemotherapy trials." Journal of Clinical Oncology, 11: 794-801.
7. Kramar, A., Lebecq, A. and Candalh, E. (1999). "Continual reassessment methods in phase I trials of the combination of two drugs in oncology." Statistics in Medicine, 18: 1849-1864.
8. Kuzuya, K., Ishikawa, H., Nakanishi, T., et al. (2001). "Optimal doses of paclitaxel and carboplatin combination chemotherapy for ovarian cancer: A phase I modified continual reassessment method study." International Journal of Clinical Oncology, 6: 271-278.
9. Leung, D. H-Y, and Wang, Y-G. (2002). "An extension of the continual reassessment method using decision theory." Statistics in Medicine, 21: 51-63.
10. M¿ller, S. (1995). "An extension of the continual reassessment methods using a pre- liminary up-and-down design in a dose finding study in cancer patients, in order to investigate a greater range of doses." Statistics in Medicine, 14: 911-922.
11. O'Quigley, J., Pepe, M., and Fisher, L. (1990). "Continual reassessment method: a practical design for phase 1 clinical trials in cancer." Biometrics, 46: 33-48.
12. Piantadosi, S., Fisher, J., and Grossman, S. (1998). "Practical implementation of a mod- ified continual reassessment method for dose finding trials." Cancer Chemotherapy and Pharmacology, 41: 429-436.
13. Storer, B. E. (1989). "Design and analysis of phase I clinical trials." Biometrics, 45: 925-937.
14. Thall, P. F., Millikan, R. E., Mueller, P. and Lee, S.-J. (2003). "Dose-finding with two agents in phase I oncology trials." Biometrics, 59: 487-496.
15. Wages, N. A., Conaway, M. R., and O'Quigley, J. (2011). "Continual reassessment method for partial ordering." Biometrics, 67: 1555-1563.
16. Wang, K. and Ivanova, A. (2005). "Two-dimensional dose-finding in discrete dose space." Biometrics, 61: 217-222.
17. Yin, G. (2012). Clinical Trial Design: Bayesian and Frequentist Adaptive Methods. New Jersey: John Wiley&Sons Inc.
18. Yin, G. and Yuan, Y. (2009a). "Bayesian model averaging continual reassessment method in phase I clinical trials." Journal of the American Statistical Association, 104: 954-968.
19. Yin, G. and Yuan, Y. (2009b). "Bayesian dose-finding in oncology for drug combinations by copula regression." Journal of the Royal Statistical Society C, 58: 211-224.
20. Yuan, Z., Chappell, R., and Bailey, H. (2007). "The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach." Biometrics, 63: 173-179.
21. Yuan, Y. and Yin, G. (2008). "Sequential continual reassessment method for two- dimensional dose-finding." Statistics in Medicine, 27: 5664-5678.